Please use this identifier to cite or link to this item:
https://doi.org/10.18632/oncotarget.28047
DC Field | Value | |
---|---|---|
dc.title | Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status | |
dc.contributor.author | Marijon, Hélène | |
dc.contributor.author | Gery, Sigal | |
dc.contributor.author | Chang, Hua | |
dc.contributor.author | Landesman, Yosef | |
dc.contributor.author | Shacham, Sharon | |
dc.contributor.author | Lee, Dhong Hyun | |
dc.contributor.author | de Gramont, Aimery | |
dc.contributor.author | Koeffler, Harold Phillip | |
dc.date.accessioned | 2022-10-13T07:34:41Z | |
dc.date.available | 2022-10-13T07:34:41Z | |
dc.date.issued | 2021-08-31 | |
dc.identifier.citation | Marijon, Hélène, Gery, Sigal, Chang, Hua, Landesman, Yosef, Shacham, Sharon, Lee, Dhong Hyun, de Gramont, Aimery, Koeffler, Harold Phillip (2021-08-31). Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status. Oncotarget 12 (18) : 1749-1762. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.28047 | |
dc.identifier.issn | 1949-2553 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/233145 | |
dc.description.abstract | Triple negative breast cancer (TNBC) is a deadly disease with limited treatment options. Selinexor is a selective inhibitor of nuclear export that binds covalently to exportin 1 thereby reactivating tumor suppressor proteins and downregulating expression of oncogenes and DNA damage repair (DDR) proteins. Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of patients with breast cancer harboring BRCA mutations. We examined the effects of co-treatment with selinexor and olaparib in TNBC cell lines. BRCA1 wildtype (BRCA1-wt) and BRCA1 mutant (BRCA1-mut) TNBC cell lines were treated with selinexor and/or olaparib and effects on cell viability and cell cycle were evaluated. The effects of treatment were also evaluated in mouse xenograft models generated with BRCA1-wt and BRCA1-mut TNBC cell lines. Treatment with selinexor inhibited cell proliferation and survival of all TNBC cell lines tested in vitro. This effect was enhanced following treatment of the cells with the combination of selinexor and olaparib, which showed synergistic effects on tumor growth inhibition in MDA-MB-468-derived (BRCA1-wt) and MDA-MB-436-derived (BRCA1-mut) xenografts. As co-treatment with selinexor and olaparib exhibits anti-tumor activity regardless of BRCA1 mutation status, the clinical implications of the combination warrant further investigation. © 2021 Marijon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
dc.publisher | Impact Journals LLC | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | Scopus OA2021 | |
dc.subject | BRCA1 | |
dc.subject | Olaparib | |
dc.subject | Selinexor | |
dc.subject | Triple negative breast cancer | |
dc.subject | XPO1 | |
dc.type | Article | |
dc.contributor.department | MEDICINE | |
dc.description.doi | 10.18632/oncotarget.28047 | |
dc.description.sourcetitle | Oncotarget | |
dc.description.volume | 12 | |
dc.description.issue | 18 | |
dc.description.page | 1749-1762 | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_18632_oncotarget_28047.pdf | 4.26 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License